MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ
1.410
+0.110
+8.46%
After Hours: 1.440 +0.03 +2.13% 16:30 02/14 EST
OPEN
1.300
PREV CLOSE
1.300
HIGH
1.540
LOW
1.300
VOLUME
518.40K
TURNOVER
--
52 WEEK HIGH
4.268
52 WEEK LOW
0.7260
MARKET CAP
87.85M
P/E (TTM)
-1.9360
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GALT last week (0210-0214)?
Weekly Report · 11h ago
Weekly Report: what happened at GALT last week (0203-0207)?
Weekly Report · 02/10 12:14
Largest borrow rate increases among liquid names
TipRanks · 02/04 13:51
Weekly Report: what happened at GALT last week (0127-0131)?
Weekly Report · 02/03 12:21
Weekly Report: what happened at GALT last week (0120-0124)?
Weekly Report · 01/27 12:26
Galectin Therapeutics Unveils Promising NAVIGATE Trial Results
TipRanks · 01/23 16:50
Weekly Report: what happened at GALT last week (0113-0117)?
Weekly Report · 01/20 12:13
Galectin Therapeutics Highlights Promising NAVIGATE Trial Results
TipRanks · 01/13 13:38
More
About GALT
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Webull offers Galectin Therapeutics Inc stock information, including NASDAQ: GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.